Sach Tissues India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 6.68 M
- Revenue Growth -1.88%
- Profit Growth -12.92%
- Ebitda 26.61%
- Net Worth 9.62%
- Total Assets 15.15%
About Sach Tissues India
Sach Tissues India Private Limited (STIPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 March 2010 and has a history of 14 years and 11 months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.68 M.
Chokkalingam Mudaliar and Umaa Thiyagarajan serve as directors at the Company.
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U21092TN2010PTC075107
- Company No.
075107
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2010
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sach Tissues India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chokkalingam Mudaliar  | Managing Director | 26-Mar-2010 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Umaa Thiyagarajan | Director | 15-Apr-2014 | Current |
Financial Performance of Sach Tissues India.
Sach Tissues India Private Limited, for the financial year ended 2017, experienced Minor drop in revenue, with a 1.88% decrease. The company also saw a substantial fall in profitability, with a 12.92% decrease in profit. The company's net worth moved up by a moderate rise of 9.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sach Tissues India?
In 2017, Sach Tissues India had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.68 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.67 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2020 | Canara Bank | ₹0.50 M | Open |
| 11 Jun 2020 | Canara Bank | ₹1.18 M | Open |
| 28 Oct 2010 | Canara Bank | ₹5.00 M | Open |
How Many Employees Work at Sach Tissues India?
Unlock and access historical data on people associated with Sach Tissues India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sach Tissues India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sach Tissues India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
